business
AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
Drugmaker’s largest deal in more than half a decade comes amid surge of M&A in sector
Read full story on Financial Times → More top storiesAlso covered by
Yahoo Finance
AbbVie to acquire Apogee Therapeutics in $10.9B deal
Bloomberg Markets
AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug | Stock Movers
Bloomberg Markets
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
Yahoo Finance
AbbVie to Buy Immunology Drugmaker Apogee for $10.9 Billion
Aggregated and edited by the Scoop newsroom. We surface news from Financial Times alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop